Axon Enterprise, Inc $AXON Shares Bought by NBH Bank

NBH Bank grew its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 5,493.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 10,908 shares of the biotechnology company’s stock after buying an additional 10,713 shares during the quarter. Axon Enterprise accounts for approximately 1.8% of NBH Bank’s portfolio, making the stock its 13th biggest position. NBH Bank’s holdings in Axon Enterprise were worth $4,609,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in AXON. State Street Corp increased its stake in shares of Axon Enterprise by 5,700.2% during the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock worth $119,724,905,000 after buying an additional 209,879,882 shares during the period. Envestnet Asset Management Inc. raised its holdings in Axon Enterprise by 18,050.2% in the second quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock valued at $7,400,094,000 after acquiring an additional 13,127,348 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Axon Enterprise by 391,214.9% in the third quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock valued at $2,952,943,000 after acquiring an additional 6,987,098 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Axon Enterprise by 5,022.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company’s stock valued at $1,802,719,000 after purchasing an additional 4,183,302 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Axon Enterprise by 8,432.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after buying an additional 3,496,493 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the sale, the president owned 296,974 shares in the company, valued at $170,590,774.82. This represents a 5.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the sale, the insider owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This represents a 8.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,397 shares of company stock worth $21,234,034 in the last 90 days. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen dropped their price target on shares of Axon Enterprise from $825.00 to $800.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Citigroup reaffirmed a “market outperform” rating on shares of Axon Enterprise in a research report on Monday, November 2nd. Argus lifted their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Needham & Company LLC reduced their price target on shares of Axon Enterprise from $750.00 to $500.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Finally, Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 price objective for the company. in a research note on Friday, November 6th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $612.18.

Trending Headlines about Axon Enterprise

These are some of the AXON headlines that stood out recently:

• Positive Sentiment: Northland maintained a $540 price target despite Axon’s steep decline from its August high, signaling that at least one analyst sees meaningful potential upside. A price target is an estimate, not a guarantee. Axon Is Down 52% From Its August High. Northland Still Sees $540
• Neutral Sentiment: Axon is investing $1.2 billion for a 37% stake in drone maker Skydio and will distribute its products to U.S. public-safety customers. The deal could broaden Axon’s offering, but its sizeable cost makes the investment a factor for investors to weigh. Axon invests $1.2B into Skydio and becomes its U.S. public safety distributor
• Negative Sentiment: Axon’s third-quarter adjusted EPS missed Wall Street expectations, and cautious guidance contributed to a sharp share decline. The company also said federal contract delays shifted $130 million of revenue out of 2026, weighing on near-term expectations. Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $315.42 on Thursday. The stock has a market cap of $25.68 billion, a P/E ratio of 101.10, a P/E/G ratio of 5.75 and a beta of 1.48. Axon Enterprise, Inc has a twelve month low of $291.45 and a twelve month high of $665.07. The stock has a 50 day moving average of $426.24 and a two-hundred day moving average of $470.65. The company has a current ratio of 3.00, a quick ratio of 2.60 and a debt-to-equity ratio of 0.76.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The business had revenue of $908.55 million for the quarter, compared to analysts’ expectations of $934.33 million. Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. The business’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business posted $1.17 earnings per share. On average, research analysts forecast that Axon Enterprise, Inc will post 2.10 earnings per share for the current year.

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.